Alcobra Company Profile (NASDAQ:ADHD)

About Alcobra (NASDAQ:ADHD)

Alcobra logoAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADHD
  • CUSIP: N/A
  • Web:
  • Market Cap: $31.15 million
  • Outstanding Shares: 27,562,000
Average Prices:
  • 50 Day Moving Avg: $1.14
  • 200 Day Moving Avg: $1.23
  • 52 Week Range: $0.83 - $5.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.40
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.61 per share
  • Price / Book: 0.70
  • EBIDTA: ($23,500,000.00)
  • Return on Equity: -45.21%
  • Return on Assets: -42.55%
  • Current Ratio: 21.08%
  • Quick Ratio: 21.08%
  • Average Volume: 236,621 shs.
  • Beta: 1.5
  • Short Ratio: 5.73
Frequently Asked Questions for Alcobra (NASDAQ:ADHD)

What is Alcobra's stock symbol?

Alcobra trades on the NASDAQ under the ticker symbol "ADHD."

How were Alcobra's earnings last quarter?

Alcobra Ltd. (NASDAQ:ADHD) issued its quarterly earnings results on Tuesday, May, 30th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. View Alcobra's Earnings History.

When will Alcobra make its next earnings announcement?

Alcobra is scheduled to release their next quarterly earnings announcement on Wednesday, August, 16th 2017. View Earnings Estimates for Alcobra.

Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?

9 brokerages have issued 1 year price targets for Alcobra's stock. Their predictions range from $1.00 to $4.00. On average, they anticipate Alcobra's stock price to reach $2.02 in the next year. View Analyst Ratings for Alcobra.

What are analysts saying about Alcobra stock?

Here are some recent quotes from research analysts about Alcobra stock:

  • 1. According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (7/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Development of new drugs carries a high failure rate, either because the drug in question fails to show efficacy or significant safety issues arise during the clinical trial process. In addition, regulatory authorities such as the Food & Drug Administration (FDA) may delay the approval process or reject Alcobra’s clinical findings." (4/13/2017)

Who are some of Alcobra's key competitors?

Who are Alcobra's key executives?

Alcobra's management team includes the folowing people:

  • Yaron Daniely, Chairman of the Board
  • David C. Baker, Interim Chief Executive Officer and Chief Commercial Officer
  • Tomer Berkovitz, Chief Financial Officer
  • Hagit Marchaim Ph.D., Senior Vice President - Regulatory Affairs
  • Hanna Ron, Senior Vice President of Chemistry, Manufacturing and Control
  • Oded Edri, Vice President - Finance
  • Johanna Schumann, Vice President - Preclinical Development
  • Jonathan Rubin M.D., Chief Medical Officer
  • Daniel E. Geffken CPA, Director
  • Aharon Schwartz, Director

Who owns Alcobra stock?

Alcobra's stock is owned by many different of retail and institutional investors. Top institutional investors include BROSH CAPITAL PARTNERS L.P. (16.50%). View Institutional Ownership Trends for Alcobra.

How do I buy Alcobra stock?

Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alcobra's stock price today?

One share of Alcobra stock can currently be purchased for approximately $1.13.

MarketBeat Community Rating for Alcobra (NASDAQ ADHD)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Alcobra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alcobra (NASDAQ:ADHD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $2.02 (78.89% upside)

Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017Jefferies Group LLCReiterated RatingHold$1.25LowView Rating Details
5/31/2017Roth CapitalSet Price TargetBuy$4.00HighView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$1.00LowView Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$2.00N/AView Rating Details
1/17/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetHold$3.00 -> $2.00N/AView Rating Details
11/2/2016WBB SecuritiesUpgradeSell -> Hold$4.00 -> $1.90N/AView Rating Details
10/28/2016Barclays PLCDowngradeEqual Weight -> Underweight$3.00 -> $2.00N/AView Rating Details
9/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyN/AView Rating Details
6/7/2016Canaccord GenuityInitiated CoverageBuyN/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for Alcobra (NASDAQ:ADHD)
Earnings by Quarter for Alcobra (NASDAQ:ADHD)
Earnings History by Quarter for Alcobra (NASDAQ ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2017($0.15)N/AView Earnings Details
5/30/20173/31/2017($0.15)($0.13)ViewN/AView Earnings Details
2/15/201712/31/2016($0.26)($0.22)ViewListenView Earnings Details
11/15/2016Q316($0.27)($0.28)$4.30 million$7.90 millionViewN/AView Earnings Details
8/30/2016Q216($0.22)($0.21)ViewListenView Earnings Details
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details
11/12/2015Q315($0.31)($0.20)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details
5/6/2015Q1 2015($0.31)($0.26)ViewN/AView Earnings Details
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details
11/17/2014Q3 14($0.61)($0.77)ViewN/AView Earnings Details
8/11/2014Q2($0.58)($0.57)ViewListenView Earnings Details
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details
11/7/2013Q313($0.28)ViewN/AView Earnings Details
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alcobra (NASDAQ:ADHD)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.15)($0.20)
Q2 20172($0.23)($0.13)($0.18)
Q3 20172($0.18)($0.14)($0.16)
Q4 20172($0.19)($0.15)($0.17)
(Data provided by Zacks Investment Research)


Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by


Headline Trends for Alcobra (NASDAQ:ADHD)
Latest Headlines for Alcobra (NASDAQ:ADHD)
DateHeadline logoBioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session - July 21 at 4:45 PM logoBioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session - July 21 at 4:45 PM logoNew Strong Buy Stocks for July 20th - July 20 at 3:50 PM logoAlcobra Ltd. (ADHD) Upgraded by Zacks Investment Research to Buy - July 18 at 10:20 PM logoZacks: Brokerages Anticipate Alcobra Ltd. (ADHD) to Post -$0.13 Earnings Per Share - June 28 at 8:18 PM logoAlcobra Ltd. (ADHD) Receives Average Recommendation of "Hold" from Analysts - June 27 at 9:26 AM logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives - June 24 at 1:55 AM logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives - - June 23 at 8:54 PM logoAlcobra Updates on its Review of Strategic Alternatives - June 23 at 3:52 PM
News IconUPDATE 1-Shire wins U.S. approval for long-acting ADHD drug - June 22 at 12:53 PM logoShire wins US approval for long-acting ADHD drug - Nasdaq - June 21 at 3:49 PM logoShire's long-acting ADHD drug wins US approval - Nasdaq - June 20 at 8:52 PM logoZacks Investment Research Lowers Alcobra Ltd. (ADHD) to Hold - June 15 at 8:50 PM logoAlcobra Ltd. (ADHD) Enters Cooperation Agreement with Brosh ... - - June 13 at 5:40 AM logoAlcobra Announces Cooperation Agreement with Brosh Group and Board Additions - June 12 at 3:54 PM logoAlcobra's (ADHD) Hold Rating Reaffirmed at Jefferies Group LLC - June 12 at 8:28 AM logoAlcobra Ltd. (ADHD) Gains on Rumors of Bid from Regenera - - June 9 at 3:25 PM logoAlcobra Ltd (ADHD) Upgraded by Zacks Investment Research to Buy - June 2 at 8:34 PM logo Brokerages Anticipate Alcobra Ltd (ADHD) Will Announce Earnings of -$0.13 Per Share - June 2 at 6:42 PM logoAlcobra Ltd (ADHD) PT Set at $4.00 by Roth Capital - June 1 at 11:02 PM logoSwiss biotech NLS Pharma's ADHD drug succeeds in mid-stage ... - Nasdaq - May 31 at 3:19 PM logoAlcobra Ltd (ADHD) Given Average Recommendation of "Hold" by Brokerages - May 31 at 10:02 AM logoAlcobra Ltd (ADHD) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS - May 31 at 7:34 AM logoAlcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release) - May 30 at 10:07 AM logoAlcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update - May 30 at 10:07 AM logoAlcobra reports 1Q loss - May 30 at 10:07 AM logoAlcobra (ADHD) CEO to Step Down, Remain on Board - May 16 at 8:20 PM logoChuck Royce Continues to Buy These 10 Stocks - May 16 at 8:20 PM logoAlcobra (ADHD) CEO to Step Down, Remain on Board - - May 15 at 3:20 PM logoAlcobra Announces Leadership Update - GlobeNewswire (press release) - May 15 at 8:09 AM logoAlcobra Announces Leadership Update - May 15 at 8:09 AM logo Analysts Anticipate Alcobra Ltd (ADHD) Will Post Earnings of -$0.20 Per Share - May 9 at 8:24 AM logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting - May 7 at 3:20 PM logoAlcobra Ltd (ADHD) Receives Consensus Rating of "Hold" from Brokerages - May 5 at 9:08 PM logoAlcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group - May 5 at 8:21 PM logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting - - May 5 at 3:20 PM logoAlcobra (ADHD) Getting Somewhat Positive News Coverage, AlphaOne Reports - May 3 at 8:32 AM logoAlcobra (ADHD) Given Daily Media Sentiment Score of 0.22 - April 30 at 11:17 AM logoSomewhat Favorable Press Coverage Very Unlikely to Impact Alcobra (ADHD) Stock Price - April 27 at 2:06 PM logoAlcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders - GlobeNewswire (press release) - April 24 at 3:21 PM logoAlcobra (ADHD) Receiving Somewhat Negative Media Coverage, AlphaOne Reports - April 24 at 11:48 AM logoAlcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders - April 24 at 11:00 AM logoAlcobra (ADHD) Receives Daily Coverage Optimism Rating of 0.31 - April 20 at 10:39 AM logoZacks Investment Research Lowers Alcobra Ltd (ADHD) to Hold - April 18 at 9:57 PM logoAlcobra Ltd (ADHD) Expected to Post Earnings of -$0.20 Per Share - April 18 at 1:22 PM logoAlcobra (ADHD) Earns Coverage Optimism Rating of 0.18 - April 17 at 10:08 AM logoZacks Investment Research Upgrades Alcobra Ltd (ADHD) to Buy - April 17 at 7:36 AM logoAlcobra (ADHD) Receiving Positive Media Coverage, Report Finds - April 14 at 1:54 PM logoAlcobra Ltd (ADHD) Given "Hold" Rating at Cantor Fitzgerald - April 13 at 9:20 PM logoExodus Capital is Summoning an Extraordinary General Meeting - April 12 at 12:11 PM



Alcobra (ADHD) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff